Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma

15Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Broad cross-talk exists between the endocrine and immune systems. Estrogen receptor expression in lymphocytes suggests that hormonal modulation may influence lymphoma risk. Analysis of genetic polymorphisms that affect oestrogen production, such as cytochrome P450 17A1 (CYP17A1) -34T>C, may provide insight into oestrogen's role in lymphomagenesis. CYP17A1 -34T>C and CYP17A1 IVS2 105A>C polymorphisms were analyzed in a non-Hodgkin lymphoma (NHL) population-based case-control study. The CYP17A1 -34CC genotype was positively associated with NHL [odds ratio (OR) = 1.44, 95% confidence interval (CI) 1.02-2.03], particularly diffuse large B-cell lymphoma (OR = 1.76, CI 1.14-2.71). Associations of CYP17A1 polymorphisms with increased risk of NHL suggest a role for oestrogen in lymphomagenesis. © 2005 Blackwell Publishing Ltd.

Cite

CITATION STYLE

APA

Skibola, C. F., Lightfoot, T., Agana, L., Smith, A., Rollinson, S., Kao, A., … Roman, E. (2005). Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma. British Journal of Haematology, 129(5), 618–621. https://doi.org/10.1111/j.1365-2141.2005.05505.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free